DRKS00033884尚未招募不适用
Follow-up of patients with transthyretin amyloid cardiomyopathy by multi-modality imaging - FAITH
Deutsches Herzzentrum der Charité0 个研究点目标入组 60 人开始时间: 2024年3月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1.Diagnosed ATTR-CM according to current standards (TTE, DPD-scintigraphy and/or biopsy) AND:
- •2.Eligible to receive treatment with Tafamidis
- •3.Informed consent
- •4.Agrees to receive note about incidental findings
- •5.Valid health insurance
排除标准
- •1.Non ATTR-CM
- •2.Severe cardiovascular comorbidities including:
- •a.Myocardial infarction within the last 6 months
- •b.After coronary stenting with in the last 6 month
- •c.After coronary artery bypass graft (CABG)
- •d.Permanent atrial fibrillation
- •3.Absolute contraindications for CMR
- •4.Allergy against gadolinium-containing contrast agent
- •5.Chronic kidney insufficiency with a GFR <30 ml/min
- •6.Pregnancy/Breastfeeding
- •7.No consent to study
研究者
相似试验
招募中
不适用
ATTR amyloidosis in patients undergoing transcatheter aortic valve replacement: from prevalence to hemodynamic consequence.AmyloidosisNL-OMON55157niversitair Medisch Centrum Groningen340
尚未招募
2 期
Effects of glavonoid for transthyretin amyloidosisJPRN-jRCTs071230091Tahara Nobuhiro40
进行中（未招募）
不适用
The purpose of this substudy is to describe the collection of bloodsamples to be used for development and validation of a biomarker assay.EUCTR2013-004090-28-ITFold RX Pharmaceuticals, a Pfizer Company45
招募中
不适用
Transthyretin amyloidosis (ATTR) in TAVR patients - establishment of a multicenter register (TAP-TAVI register)I43.1I35.0Cardiomyopathy in metabolic diseasesAortic (valve) stenosisDRKS00025129niklinik Köln, Kardiologie600
已完成
不适用
Neuropathy in Patients Monitored for Wild-type TTR Cardiac Amyloidosis (Non-mutated)Wild-type Amyloid CardiopathyNCT04828928University Hospital, Bordeaux65